** Shares of generic drugmaker Viatris VTRS.O fall 11.3% to $9.97 premarket
** Co forecast 2025 revenue to be between $13.5 bln and $14 bln, below analysts' est of $14.27 bln - LSEG
** Co expects 2025 adj profit between $2.12/shr and $2.26/shr, compared with estimates of $2.59/shr - LSEG
** VTRS says it estimates FDA action will negatively impact its 2025 total revenues by about $500 mln and adjusted core earnings by roughly $385 mln.
** Last year, FDA has restricted imports from Viatris' Indore facility in India due to regulatory violations
** Co also reports Q4 adj profit of 54 cents/shr, below analysts' est of 57 cents/shr - LSEG
** Co posts Q4 sales of $3.52 bln, below analysts' est of $3.61 bln - LSEG
** VTRS gained 8.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。